HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
KL0Ty73UWNueteTh